Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib in PIK3CA-Mutant Solid Tumors and Breast Cancer
NCT03006172Phase 1Active, not recruiting
- Sponsor
- Genentech
- Start
- Dec 2016
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of inavolisib in breast cancer and solid tumor (7 arms), sponsored by Genentech. Primary endpoints: Percentage of Participants With Dose Limiting Toxicities, Recommended Phase II Dose of Inavolisib and 1 more. Started Dec 2016; status: active, not recruiting.
02
Drugs
inavolisib
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT03006172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03006172.